Actifio, Inc. specializes in copy data virtualization solutions, providing businesses with the tools to manage and protect their data effectively. Its flagship product, Actifio CDS, supports diverse applications and storage systems, catering to large-scale deployments in various data center environments. The company also offers Actifio Sky, designed for distributed enterprises, and Big Data Director, which assists in safeguarding large-scale file systems. Actifio Resiliency Director enables automated recovery and testing, while Actifio One provides a cloud-based service for managed data services, including backup and recovery options. Additionally, OnVault serves as a long-term data retention solution that facilitates data reuse for analytics and compliance purposes. With a presence in over 30 countries and strategic partnerships, Actifio enables organizations to virtualize their data, enhancing business agility and resilience while reducing costs. The company, founded in 2009, is headquartered in Waltham, Massachusetts, with operations in several other countries including India, Australia, and Germany.
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.
Private Equity Round in 2018
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
Oasys (Osmotic Application Systems) is a privately held Boston, MA based company developing a suite of proprietary energy and resource recovery products to address the growing, global water crisis. Engineered Osmosisâ„¢ (EOâ„¢) is a platform for reducing cost in the production of clean water, power and energy through more efficient and sustainable utilization of resources.
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has a preclinical development program for treating chronic kidney disease (CKD).
Planful, Inc. is a company that specializes in developing a cloud-based financial planning and analysis platform designed to enhance enterprise performance management. Its software suite facilitates budgeting, forecasting, consolidation, and financial reporting, while also providing tools for cash flow forecasting, annual operating planning, and workforce planning. By automating manual processes and enabling rolling forecasts, Planful aims to streamline financial operations and improve strategic decision-making across various industries, including life sciences, manufacturing, and non-profit sectors. The platform also supports multi-dimensional ad hoc analysis and enhances collaboration and workflow among teams. Originally known as Host Analytics, Inc., the company rebranded to Planful, Inc. in December 2019 and operates from its headquarters in Redwood City, California, with additional offices in Scottsdale, Arizona, and Hyderabad, India.
On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
Only Evergage’s real-time personalization platform delivers The Power of 1, enabling digital marketers to transform the dream of 1:1 customer engagement into reality.
Combining in-depth behavioral analytics with customer data, Evergage provides the one platform you need to systematically understand and interact with each person that visits your site or uses your app – one at a time, “in the moment” and at scale – to deliver a maximally relevant, individualized experience.
Personalization is the future of digital marketing, and we believe it should be easy for marketers – without the need for developers or IT – to understand their audiences and respond in real time with the most engaging experiences and the most relevant recommendations. Our customers delight their visitors, prospects and customers every day, building valuable relationships that lead to greater revenues and customer loyalty.
Evergage has delivered personalized experiences to more than 2 billion web visitors and users of over 150 organizations, including Academy Sports+Outdoors, Endurance International Group, Intuit, Publishers Clearing House, Rue La La, Zumiez and more.
Founded in 2010 and based in Somerville, MA, Evergage is a two-time winner in the Golden Bridge Awards, Stevie American Business Awards, Best in Biz Awards and MITX Awards; a two-time BostInno “50 on Fire” finalist; and a TechCrunch Disrupt finalist.
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.
Actifio, Inc. specializes in copy data virtualization solutions, providing businesses with the tools to manage and protect their data effectively. Its flagship product, Actifio CDS, supports diverse applications and storage systems, catering to large-scale deployments in various data center environments. The company also offers Actifio Sky, designed for distributed enterprises, and Big Data Director, which assists in safeguarding large-scale file systems. Actifio Resiliency Director enables automated recovery and testing, while Actifio One provides a cloud-based service for managed data services, including backup and recovery options. Additionally, OnVault serves as a long-term data retention solution that facilitates data reuse for analytics and compliance purposes. With a presence in over 30 countries and strategic partnerships, Actifio enables organizations to virtualize their data, enhancing business agility and resilience while reducing costs. The company, founded in 2009, is headquartered in Waltham, Massachusetts, with operations in several other countries including India, Australia, and Germany.
PowerVision, Inc. is a company that specializes in the development of innovative accommodating intraocular lens technology aimed at restoring vision for individuals affected by presbyopia and cataracts. Based in Belmont, California, PowerVision's flagship product, the FluidVision intraocular lens, utilizes a small amount of fluid within the lens to mimic the natural functioning of a healthy eye, allowing users to dynamically adjust their focus for clear vision at all distances. This technology is designed to address the vision needs of millions, particularly the elderly, who suffer from cataracts and the age-related loss of near vision associated with presbyopia. By offering a solution that potentially eliminates the need for glasses or other forms of vision correction, PowerVision aims to significantly improve the quality of life for those facing these common age-related vision challenges. The company was incorporated in 2002 and was acquired by Alcon Laboratories, Inc. in March 2019.
Aquion Energy is fundamentally changing the economics of power generation, transmission and distribution by developing and commercializing cost-effective energy storage solutions that are safe, reliable, and sustainable from nontoxic components as simple as saltwater. Based on the research of Carnegie Mellon University Professor Jay Whitacre, Aquion's proprietary Aqueous Hybrid Ion (AHI™) battery overcomes the pitfalls of conventional energy storage technologies. AHI systems enhance the electrical grid by providing flexible, emissions-free capacity that optimizes existing generation assets and enables broad adoption of renewable energy technologies.
Aquion Energy is fundamentally changing the economics of power generation, transmission and distribution by developing and commercializing cost-effective energy storage solutions that are safe, reliable, and sustainable from nontoxic components as simple as saltwater. Based on the research of Carnegie Mellon University Professor Jay Whitacre, Aquion's proprietary Aqueous Hybrid Ion (AHI™) battery overcomes the pitfalls of conventional energy storage technologies. AHI systems enhance the electrical grid by providing flexible, emissions-free capacity that optimizes existing generation assets and enables broad adoption of renewable energy technologies.
Astria Therapeutics, formerly Catabasis Pharmaceuticals, is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of innovative therapeutics aimed at treating inflammatory conditions. Its lead product candidate, edasalonexent, is an oral small molecule currently undergoing Phase III clinical trials for the treatment of Duchenne muscular dystrophy. Additionally, Astria Therapeutics is advancing CAT-5571, targeted for cystic fibrosis. The company engages in collaborative research efforts, including a partnership with the Jain Foundation to explore edasalonexent's potential in dysferlinopathy and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in tuberculosis. Founded in 2008, Astria Therapeutics leverages its platform technology to develop small molecules that specifically target pathways involved in the inflammatory response, aiming to create novel therapies for various inflammatory diseases.
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule therapeutics for cancer treatment. The company focuses on targeting tumor metabolism and tumor immunology to create innovative anti-cancer drugs. Its lead product candidate, CB-839, is an inhibitor of glutaminase currently undergoing Phase II clinical trials for solid tumors. Additionally, Calithera is developing CB-1158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology indications. The company is also working on other candidates, including CB-280 for cystic fibrosis and CB-708, an inhibitor of CD73. Calithera has established collaborations with major pharmaceutical firms, including Bristol-Myers Squibb and Incyte Corporation, to advance its research and development efforts. Founded in 2010, Calithera aims to address critical challenges in cancer therapy through its specialized drug development pipeline.
Fuze is a cloud-based unified communications platform that enhances productivity and collaboration within organizations. It offers tools for simplified voice communications, flexible video conferencing, and continuous collaboration, allowing modern, mobile workforces to communicate seamlessly across various devices. Fuze’s platform aggregates data from multiple sources, providing valuable insights that help business leaders understand and improve their operations and workforce dynamics. Founded in 2002 and originally known as ThinkingPhones, Fuze is headquartered in Boston, Massachusetts, with additional offices in various global cities, including New York, San Francisco, and London. The company serves a diverse clientele, including well-known organizations such as CareerBuilder, Fujitsu, and Oregon Health & Sciences University.
Coskata, Inc. is a biology-based renewable energy company, with technology for the production of liquid fuels. Using proprietary microorganisms and transformative bioreactor designs, the company will produce ethanol from a wide variety of input materials to provide economic, environmental, and national security benefits.
Rive Technology is a clean energy company focused on advancing catalyst technology for petroleum refining. The company has developed a proprietary catalyst, originally invented at MIT, that enhances the efficiency of traditional zeolite catalysts. This innovation allows for improved access to large hydrocarbon molecules, significantly increasing the yield of gasoline and diesel fuel produced from each barrel of crude oil. Rive's catalyst is designed to integrate seamlessly into existing refinery operations, enabling refiners to boost production and profitability without requiring substantial capital investment. By optimizing diffusion-limited reactions, Rive Technology aims to transform the petroleum refining process and contribute to more sustainable energy solutions.
Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases.
Planful, Inc. is a company that specializes in developing a cloud-based financial planning and analysis platform designed to enhance enterprise performance management. Its software suite facilitates budgeting, forecasting, consolidation, and financial reporting, while also providing tools for cash flow forecasting, annual operating planning, and workforce planning. By automating manual processes and enabling rolling forecasts, Planful aims to streamline financial operations and improve strategic decision-making across various industries, including life sciences, manufacturing, and non-profit sectors. The platform also supports multi-dimensional ad hoc analysis and enhances collaboration and workflow among teams. Originally known as Host Analytics, Inc., the company rebranded to Planful, Inc. in December 2019 and operates from its headquarters in Redwood City, California, with additional offices in Scottsdale, Arizona, and Hyderabad, India.
Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.
Astria Therapeutics, formerly Catabasis Pharmaceuticals, is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of innovative therapeutics aimed at treating inflammatory conditions. Its lead product candidate, edasalonexent, is an oral small molecule currently undergoing Phase III clinical trials for the treatment of Duchenne muscular dystrophy. Additionally, Astria Therapeutics is advancing CAT-5571, targeted for cystic fibrosis. The company engages in collaborative research efforts, including a partnership with the Jain Foundation to explore edasalonexent's potential in dysferlinopathy and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in tuberculosis. Founded in 2008, Astria Therapeutics leverages its platform technology to develop small molecules that specifically target pathways involved in the inflammatory response, aiming to create novel therapies for various inflammatory diseases.
Planful, Inc. is a company that specializes in developing a cloud-based financial planning and analysis platform designed to enhance enterprise performance management. Its software suite facilitates budgeting, forecasting, consolidation, and financial reporting, while also providing tools for cash flow forecasting, annual operating planning, and workforce planning. By automating manual processes and enabling rolling forecasts, Planful aims to streamline financial operations and improve strategic decision-making across various industries, including life sciences, manufacturing, and non-profit sectors. The platform also supports multi-dimensional ad hoc analysis and enhances collaboration and workflow among teams. Originally known as Host Analytics, Inc., the company rebranded to Planful, Inc. in December 2019 and operates from its headquarters in Redwood City, California, with additional offices in Scottsdale, Arizona, and Hyderabad, India.
GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule therapeutics for cancer treatment. The company focuses on targeting tumor metabolism and tumor immunology to create innovative anti-cancer drugs. Its lead product candidate, CB-839, is an inhibitor of glutaminase currently undergoing Phase II clinical trials for solid tumors. Additionally, Calithera is developing CB-1158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology indications. The company is also working on other candidates, including CB-280 for cystic fibrosis and CB-708, an inhibitor of CD73. Calithera has established collaborations with major pharmaceutical firms, including Bristol-Myers Squibb and Incyte Corporation, to advance its research and development efforts. Founded in 2010, Calithera aims to address critical challenges in cancer therapy through its specialized drug development pipeline.
Modria, Inc. is a developer of a cloud-based online dispute resolution platform that automates the resolution of customer disputes in eCommerce. Founded in 2011 and headquartered in San Jose, California, with an additional office in Chennai, India, Modria serves a diverse clientele, including tangible goods and service marketplaces, payment networks, medium and large online merchants, government agencies, and classified sites. The platform seamlessly integrates with the back-end architecture and front-end user experience of eCommerce sites, allowing businesses to quickly resolve customer issues without human intervention. As of May 30, 2017, Modria operates as a subsidiary of Tyler Technologies, Inc.
Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has a preclinical development program for treating chronic kidney disease (CKD).
Fuze is a cloud-based unified communications platform that enhances productivity and collaboration within organizations. It offers tools for simplified voice communications, flexible video conferencing, and continuous collaboration, allowing modern, mobile workforces to communicate seamlessly across various devices. Fuze’s platform aggregates data from multiple sources, providing valuable insights that help business leaders understand and improve their operations and workforce dynamics. Founded in 2002 and originally known as ThinkingPhones, Fuze is headquartered in Boston, Massachusetts, with additional offices in various global cities, including New York, San Francisco, and London. The company serves a diverse clientele, including well-known organizations such as CareerBuilder, Fujitsu, and Oregon Health & Sciences University.
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.
QuickPay was founded in 2010 with a vision to leverage trends in mobile technology to remove the pain and hassle of finding, accessing, and paying for parking and transportation. Their revolutionary QP QuickPay mobile parking platform offers users one mobile parking application that works across all parking environments — drivers can even raise parking gates using their mobile phones — and gives parking owners and operators an efficient way to enable mobile parking across all their assets with a single integrated solution. Today drivers can use QP QuickPay and a mobile phone to find and pay for parking at hundreds of locations across the U.S., with new locations being added continually.
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.
Only Evergage’s real-time personalization platform delivers The Power of 1, enabling digital marketers to transform the dream of 1:1 customer engagement into reality.
Combining in-depth behavioral analytics with customer data, Evergage provides the one platform you need to systematically understand and interact with each person that visits your site or uses your app – one at a time, “in the moment” and at scale – to deliver a maximally relevant, individualized experience.
Personalization is the future of digital marketing, and we believe it should be easy for marketers – without the need for developers or IT – to understand their audiences and respond in real time with the most engaging experiences and the most relevant recommendations. Our customers delight their visitors, prospects and customers every day, building valuable relationships that lead to greater revenues and customer loyalty.
Evergage has delivered personalized experiences to more than 2 billion web visitors and users of over 150 organizations, including Academy Sports+Outdoors, Endurance International Group, Intuit, Publishers Clearing House, Rue La La, Zumiez and more.
Founded in 2010 and based in Somerville, MA, Evergage is a two-time winner in the Golden Bridge Awards, Stevie American Business Awards, Best in Biz Awards and MITX Awards; a two-time BostInno “50 on Fire” finalist; and a TechCrunch Disrupt finalist.
EndPlay is a leading provider of SaaS Content Management, Engagement and Monetization solutions delivered in the cloud. Powered by its unique 'Intelligent Rendering' technology, EndPlay's end-to-end Platform provides a streamlined user experience that empowers clients to seamlessly produce, manage and instantly deliver content optimized for virtually any device. The company's extensible architecture and integrated partners ensure EndPlay clients can expand, engage, monetize and leverage their content management solution against the complexities facing all brands in the era of Big Data and Quantum Content. Enterprise clients in media, entertainment, consumer packaged goods (CPG) and education verticals have turned to EndPlay's experienced Client Services team to support collaboration, implementation and optimization of their EndPlay solutions. EndPlay’s commitment to innovation and customer-centric approach enables clients to stay ahead of their competition, increase audience engagement, and future-proof their digital business investment. All EndPlay associates are certified to meet the company's rigorous standards of customer service. Partners and clients can also leverage EndPlay's certification process to increase platform productivity and achieve business goals. EndPlay is headquartered in Los Angeles, California with regional offices in Florida and New Jersey, and currently expanding to Europe and Asia. For more information, visit www.endplay.com.
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.
GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.
Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.
Astria Therapeutics, formerly Catabasis Pharmaceuticals, is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of innovative therapeutics aimed at treating inflammatory conditions. Its lead product candidate, edasalonexent, is an oral small molecule currently undergoing Phase III clinical trials for the treatment of Duchenne muscular dystrophy. Additionally, Astria Therapeutics is advancing CAT-5571, targeted for cystic fibrosis. The company engages in collaborative research efforts, including a partnership with the Jain Foundation to explore edasalonexent's potential in dysferlinopathy and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in tuberculosis. Founded in 2008, Astria Therapeutics leverages its platform technology to develop small molecules that specifically target pathways involved in the inflammatory response, aiming to create novel therapies for various inflammatory diseases.
Actifio, Inc. specializes in copy data virtualization solutions, providing businesses with the tools to manage and protect their data effectively. Its flagship product, Actifio CDS, supports diverse applications and storage systems, catering to large-scale deployments in various data center environments. The company also offers Actifio Sky, designed for distributed enterprises, and Big Data Director, which assists in safeguarding large-scale file systems. Actifio Resiliency Director enables automated recovery and testing, while Actifio One provides a cloud-based service for managed data services, including backup and recovery options. Additionally, OnVault serves as a long-term data retention solution that facilitates data reuse for analytics and compliance purposes. With a presence in over 30 countries and strategic partnerships, Actifio enables organizations to virtualize their data, enhancing business agility and resilience while reducing costs. The company, founded in 2009, is headquartered in Waltham, Massachusetts, with operations in several other countries including India, Australia, and Germany.
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule therapeutics for cancer treatment. The company focuses on targeting tumor metabolism and tumor immunology to create innovative anti-cancer drugs. Its lead product candidate, CB-839, is an inhibitor of glutaminase currently undergoing Phase II clinical trials for solid tumors. Additionally, Calithera is developing CB-1158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology indications. The company is also working on other candidates, including CB-280 for cystic fibrosis and CB-708, an inhibitor of CD73. Calithera has established collaborations with major pharmaceutical firms, including Bristol-Myers Squibb and Incyte Corporation, to advance its research and development efforts. Founded in 2010, Calithera aims to address critical challenges in cancer therapy through its specialized drug development pipeline.
On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.
Aquion Energy is fundamentally changing the economics of power generation, transmission and distribution by developing and commercializing cost-effective energy storage solutions that are safe, reliable, and sustainable from nontoxic components as simple as saltwater. Based on the research of Carnegie Mellon University Professor Jay Whitacre, Aquion's proprietary Aqueous Hybrid Ion (AHI™) battery overcomes the pitfalls of conventional energy storage technologies. AHI systems enhance the electrical grid by providing flexible, emissions-free capacity that optimizes existing generation assets and enables broad adoption of renewable energy technologies.
PowerVision, Inc. is a company that specializes in the development of innovative accommodating intraocular lens technology aimed at restoring vision for individuals affected by presbyopia and cataracts. Based in Belmont, California, PowerVision's flagship product, the FluidVision intraocular lens, utilizes a small amount of fluid within the lens to mimic the natural functioning of a healthy eye, allowing users to dynamically adjust their focus for clear vision at all distances. This technology is designed to address the vision needs of millions, particularly the elderly, who suffer from cataracts and the age-related loss of near vision associated with presbyopia. By offering a solution that potentially eliminates the need for glasses or other forms of vision correction, PowerVision aims to significantly improve the quality of life for those facing these common age-related vision challenges. The company was incorporated in 2002 and was acquired by Alcon Laboratories, Inc. in March 2019.
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.
Only Evergage’s real-time personalization platform delivers The Power of 1, enabling digital marketers to transform the dream of 1:1 customer engagement into reality.
Combining in-depth behavioral analytics with customer data, Evergage provides the one platform you need to systematically understand and interact with each person that visits your site or uses your app – one at a time, “in the moment” and at scale – to deliver a maximally relevant, individualized experience.
Personalization is the future of digital marketing, and we believe it should be easy for marketers – without the need for developers or IT – to understand their audiences and respond in real time with the most engaging experiences and the most relevant recommendations. Our customers delight their visitors, prospects and customers every day, building valuable relationships that lead to greater revenues and customer loyalty.
Evergage has delivered personalized experiences to more than 2 billion web visitors and users of over 150 organizations, including Academy Sports+Outdoors, Endurance International Group, Intuit, Publishers Clearing House, Rue La La, Zumiez and more.
Founded in 2010 and based in Somerville, MA, Evergage is a two-time winner in the Golden Bridge Awards, Stevie American Business Awards, Best in Biz Awards and MITX Awards; a two-time BostInno “50 on Fire” finalist; and a TechCrunch Disrupt finalist.
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
Rive Technology is a clean energy company focused on advancing catalyst technology for petroleum refining. The company has developed a proprietary catalyst, originally invented at MIT, that enhances the efficiency of traditional zeolite catalysts. This innovation allows for improved access to large hydrocarbon molecules, significantly increasing the yield of gasoline and diesel fuel produced from each barrel of crude oil. Rive's catalyst is designed to integrate seamlessly into existing refinery operations, enabling refiners to boost production and profitability without requiring substantial capital investment. By optimizing diffusion-limited reactions, Rive Technology aims to transform the petroleum refining process and contribute to more sustainable energy solutions.
Astria Therapeutics, formerly Catabasis Pharmaceuticals, is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of innovative therapeutics aimed at treating inflammatory conditions. Its lead product candidate, edasalonexent, is an oral small molecule currently undergoing Phase III clinical trials for the treatment of Duchenne muscular dystrophy. Additionally, Astria Therapeutics is advancing CAT-5571, targeted for cystic fibrosis. The company engages in collaborative research efforts, including a partnership with the Jain Foundation to explore edasalonexent's potential in dysferlinopathy and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in tuberculosis. Founded in 2008, Astria Therapeutics leverages its platform technology to develop small molecules that specifically target pathways involved in the inflammatory response, aiming to create novel therapies for various inflammatory diseases.
Actifio, Inc. specializes in copy data virtualization solutions, providing businesses with the tools to manage and protect their data effectively. Its flagship product, Actifio CDS, supports diverse applications and storage systems, catering to large-scale deployments in various data center environments. The company also offers Actifio Sky, designed for distributed enterprises, and Big Data Director, which assists in safeguarding large-scale file systems. Actifio Resiliency Director enables automated recovery and testing, while Actifio One provides a cloud-based service for managed data services, including backup and recovery options. Additionally, OnVault serves as a long-term data retention solution that facilitates data reuse for analytics and compliance purposes. With a presence in over 30 countries and strategic partnerships, Actifio enables organizations to virtualize their data, enhancing business agility and resilience while reducing costs. The company, founded in 2009, is headquartered in Waltham, Massachusetts, with operations in several other countries including India, Australia, and Germany.
Qumu Corporation specializes in providing comprehensive tools for the creation, management, security, distribution, and delivery of live and on-demand video content tailored for enterprises. The company offers an end-to-end solution that includes software licenses, server appliances, software-enabled devices, and a cloud-hosted software-as-a-service platform. In addition to these products, Qumu provides maintenance, support, and professional services to enhance user experience. Its offerings cater to various sectors, including banking, finance, insurance, manufacturing, technology, healthcare, and government, through both direct sales and partnerships. Established in 1978 and headquartered in Minneapolis, Minnesota, Qumu was previously known as Rimage Corporation before rebranding in 2013.
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.
NeuroVista Corporation, a medical device company, develops medical technologies for the management and treatment of epilepsy in the United States. It offers advisory technologies to help mitigate the uncertainty of when epileptic seizures may strike. The company was formerly known as BioNeuronics Corporation and changed its name to NeuroVista Corporation in May 2007. NeuroVista Corporation was incorporated in 2002 and is based in Seattle, Washington.
Calxeda provides revolutionary efficiency to the data center. Leveraging ultra-low power technology from ARM, servers built on Calxeda’s silicon and software platform consume a fraction of the power and space of today’s best-in-class servers, enabling data centers to realize significant reduction in capital and operating expenses. The Calxeda platform scales efficiently to thousands of server nodes, with unique network and storage acceleration, and is enhanced with management technology to deliver true “energy-proportional” computing. The result is a stunning breakthrough in performance efficiency, density, and scalability.
Coskata, Inc. is a biology-based renewable energy company, with technology for the production of liquid fuels. Using proprietary microorganisms and transformative bioreactor designs, the company will produce ethanol from a wide variety of input materials to provide economic, environmental, and national security benefits.
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule therapeutics for cancer treatment. The company focuses on targeting tumor metabolism and tumor immunology to create innovative anti-cancer drugs. Its lead product candidate, CB-839, is an inhibitor of glutaminase currently undergoing Phase II clinical trials for solid tumors. Additionally, Calithera is developing CB-1158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology indications. The company is also working on other candidates, including CB-280 for cystic fibrosis and CB-708, an inhibitor of CD73. Calithera has established collaborations with major pharmaceutical firms, including Bristol-Myers Squibb and Incyte Corporation, to advance its research and development efforts. Founded in 2010, Calithera aims to address critical challenges in cancer therapy through its specialized drug development pipeline.
Acceleron Pharma Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company is known for luspatercept-aamt, marketed as REBLOZYL, which treats anemia in adult patients with beta-thalassemia. Additionally, it is developing luspatercept-aamt for myelodysplastic syndromes and myelofibrosis, while Sotatercept targets pulmonary arterial hypertension. Acceleron is also advancing ACE-083, a neuromuscular candidate in Phase II trials aimed at Charcot-Marie-Tooth disease. The company's research focuses on biotherapeutics that influence the growth of bone, muscle, fat, and blood vessels to address conditions such as cancer-related bone and muscle loss, as well as various metabolic disorders. Founded in 2003 and based in Cambridge, Massachusetts, Acceleron has established collaborations with Celgene Corporation and Fulcrum Therapeutics to enhance its therapeutic offerings in the pulmonary disease space.
Planful, Inc. is a company that specializes in developing a cloud-based financial planning and analysis platform designed to enhance enterprise performance management. Its software suite facilitates budgeting, forecasting, consolidation, and financial reporting, while also providing tools for cash flow forecasting, annual operating planning, and workforce planning. By automating manual processes and enabling rolling forecasts, Planful aims to streamline financial operations and improve strategic decision-making across various industries, including life sciences, manufacturing, and non-profit sectors. The platform also supports multi-dimensional ad hoc analysis and enhances collaboration and workflow among teams. Originally known as Host Analytics, Inc., the company rebranded to Planful, Inc. in December 2019 and operates from its headquarters in Redwood City, California, with additional offices in Scottsdale, Arizona, and Hyderabad, India.
Altura Medical is an emerging medical device company based in Menlo Park, CA that is developing a next generation endograft technology to treat abdominal aortic aneurysms (“AAA”) and other related disease states. Development of the company’s highly differentiated technology is led by an experienced management team and supported by a prestigious syndicate of venture capital investors.
Zeltiq (pronounced Zel ′teek) Aesthetics, founded in 2005, is a science-based medical device company dedicated to the development of non-invasive procedures for the reduction of unwanted fat tissue. The Zeltiq approach utilizes a patented method called Cryolipolysis™ (the use of precisely controlled cooling to remove fat) that is designed to target only fat cells and not harm the skin or other tissue. The Zeltiq device is cleared by the FDA in the Unites States for various applications related to skin cooling during dermatologic treatments.
Astria Therapeutics, formerly Catabasis Pharmaceuticals, is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of innovative therapeutics aimed at treating inflammatory conditions. Its lead product candidate, edasalonexent, is an oral small molecule currently undergoing Phase III clinical trials for the treatment of Duchenne muscular dystrophy. Additionally, Astria Therapeutics is advancing CAT-5571, targeted for cystic fibrosis. The company engages in collaborative research efforts, including a partnership with the Jain Foundation to explore edasalonexent's potential in dysferlinopathy and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in tuberculosis. Founded in 2008, Astria Therapeutics leverages its platform technology to develop small molecules that specifically target pathways involved in the inflammatory response, aiming to create novel therapies for various inflammatory diseases.
Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers a range of products, including the EsophyX technology, which facilitates transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication (TIF) procedure. Additionally, it provides SerosaFuse Fasteners, a non-resorbable material that matches the strength of traditional sutures. EndoGastric Solutions also supports healthcare professionals through training courses and various consultative services. Established in 2002 and headquartered in Redmond, Washington, with an office in San Mateo, California, the company has evolved from its original name, EsophyX, Inc., which it adopted in 2005.
Silicor Materials Inc., formerly known as Calisolar Inc., is a manufacturer specializing in solar silicon and aluminum-based products aimed at producing low-cost photovoltaic solar cells. The company offers solar silicon products that serve as an economical alternative to traditional electronic-grade silicon, allowing photovoltaic module manufacturers to reduce costs while maintaining high performance standards. Silicor operates silicon purification facilities through its subsidiary in Ontario, Canada, and has additional manufacturing sites in Vaughan, Canada, and Mississippi. The company also produces aluminum by-products, including aluminum-silicon master alloys and polyaluminum chloride for water treatment applications. Established in 2006 and headquartered in San Jose, California, Silicor Materials further invests in innovation through its state-of-the-art research and development center located in Berlin, Germany.
Planful, Inc. is a company that specializes in developing a cloud-based financial planning and analysis platform designed to enhance enterprise performance management. Its software suite facilitates budgeting, forecasting, consolidation, and financial reporting, while also providing tools for cash flow forecasting, annual operating planning, and workforce planning. By automating manual processes and enabling rolling forecasts, Planful aims to streamline financial operations and improve strategic decision-making across various industries, including life sciences, manufacturing, and non-profit sectors. The platform also supports multi-dimensional ad hoc analysis and enhances collaboration and workflow among teams. Originally known as Host Analytics, Inc., the company rebranded to Planful, Inc. in December 2019 and operates from its headquarters in Redwood City, California, with additional offices in Scottsdale, Arizona, and Hyderabad, India.
Nuventix is an active thermal management solutions company located in Austin, Texas. The Nuventix-developed SynJet® module is a newly patented synthetic jet cooling technology that utilizes turbulent pulses of air generated from an electromagnetic actuator. Based on early success with computer cooling, Nuventix's innovative approach to LED cooling is propelling that market forward two years ahead of analyst estimates - truly affecting the industry and allowing general illumination designs to harvest the efficiencies of the LED.
GI Dynamics, Inc. is a medical device company that focuses on developing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company's flagship product, EndoBarrier, is designed to help patients manage these conditions effectively. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts, and markets its products primarily in Europe, the Middle East, the Asia Pacific, and South America. The company serves healthcare providers and third-party distributors, aiming to provide innovative solutions for metabolic diseases.
Oasys (Osmotic Application Systems) is a privately held Boston, MA based company developing a suite of proprietary energy and resource recovery products to address the growing, global water crisis. Engineered Osmosisâ„¢ (EOâ„¢) is a platform for reducing cost in the production of clean water, power and energy through more efficient and sustainable utilization of resources.
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.
CombineNet, Inc. is the advanced sourcing technology company, with over 10 years of delivering strong value to mid-sized and global organizations alike, across nearly all industries, as they make supplier and spend decisions on products and services. CombineNet's product ASAP (Advanced Sourcing Application Platform) is a web-based software-as-a-service solution that allows sourcing teams in any spend category to speed and simplify the creation, launch, and management of sourcing events of any size, scale, or complexity.
Coskata, Inc. is a biology-based renewable energy company, with technology for the production of liquid fuels. Using proprietary microorganisms and transformative bioreactor designs, the company will produce ethanol from a wide variety of input materials to provide economic, environmental, and national security benefits.
Silicor Materials Inc., formerly known as Calisolar Inc., is a manufacturer specializing in solar silicon and aluminum-based products aimed at producing low-cost photovoltaic solar cells. The company offers solar silicon products that serve as an economical alternative to traditional electronic-grade silicon, allowing photovoltaic module manufacturers to reduce costs while maintaining high performance standards. Silicor operates silicon purification facilities through its subsidiary in Ontario, Canada, and has additional manufacturing sites in Vaughan, Canada, and Mississippi. The company also produces aluminum by-products, including aluminum-silicon master alloys and polyaluminum chloride for water treatment applications. Established in 2006 and headquartered in San Jose, California, Silicor Materials further invests in innovation through its state-of-the-art research and development center located in Berlin, Germany.
Anagran's flow-based traffic management products eliminate the potentially crippling effects of network congestion to enable video, voice, data and wireless traffic to economically scale with flawless quality over converged IP networks. Anagran's products protect all key network traffic by managing end-to-end flows based on their behavior to ensure required quality and performance levels. Its products dynamically manages all network traffic regardless of application, protocol, or format, without using invasive, performance-limiting deep packet inspection(DPI) techniques. Service providers and enterprises can consistently deliver the highest levels of guaranteed performance and quality while significantly reducing capital equipment and recurring network costs. Anagran was founded by Internet pioneer Dr. Larry Roberts, recognized as one of the founding fathers of the Internet.
On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.
Onyx Pharmaceuticals (NASDAQ: ONXX) is a biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases.
ChannelAdvisor is a prominent provider of cloud-based e-commerce solutions that assist retailers and manufacturers in enhancing the scale and profitability of their global sales across various online platforms, including Amazon, Google, eBay, and Facebook. By utilizing automation, analytics, and optimization, ChannelAdvisor simplifies the process of listing and advertising products through a unified inventory feed, effectively connecting suppliers with consumers to drive sales. The company facilitates billions of dollars in sales annually and is relied upon by numerous customers, such as Eddie Bauer, Jockey, and eBags, to significantly expand their businesses. ChannelAdvisor is headquartered in Research Triangle Park, North Carolina.
GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.
AltaRock Energy is a renewable energy development company focused on the research and development of Engineered Geothermal Systems (“EGSâ€). AltaRock has filed patent applications for a portfolio of patents in the EGS area and holds exclusive licenses for related intellectual property.
The company has its corporate headquarters in Sausalito, CA and its technology development office in Seattle, WA. Its principals include Don O'Shei, Chief Executive Officer, and Susan Petty, President/Chief Technology Officer and an AltaRock Energy founder.
Qumu Corporation specializes in providing comprehensive tools for the creation, management, security, distribution, and delivery of live and on-demand video content tailored for enterprises. The company offers an end-to-end solution that includes software licenses, server appliances, software-enabled devices, and a cloud-hosted software-as-a-service platform. In addition to these products, Qumu provides maintenance, support, and professional services to enhance user experience. Its offerings cater to various sectors, including banking, finance, insurance, manufacturing, technology, healthcare, and government, through both direct sales and partnerships. Established in 1978 and headquartered in Minneapolis, Minnesota, Qumu was previously known as Rimage Corporation before rebranding in 2013.
Rive Technology is a clean energy company focused on advancing catalyst technology for petroleum refining. The company has developed a proprietary catalyst, originally invented at MIT, that enhances the efficiency of traditional zeolite catalysts. This innovation allows for improved access to large hydrocarbon molecules, significantly increasing the yield of gasoline and diesel fuel produced from each barrel of crude oil. Rive's catalyst is designed to integrate seamlessly into existing refinery operations, enabling refiners to boost production and profitability without requiring substantial capital investment. By optimizing diffusion-limited reactions, Rive Technology aims to transform the petroleum refining process and contribute to more sustainable energy solutions.
Wakonda Technologies was founded in 2005 by Dr. Les Fritzemeier and Professor Ryne Raffaelle of the Rochester Institute of Technology. The company was established to exploit the intersection of their respective skills in metallurgical processing and advanced photovoltaic devices. Wakonda was started in Rochester NY and used the facilities at RIT, Cornell University and several government agencies to conduct proof of concept experiments. In 2008, the company moved to Massachusetts to accelerate product development and early commercialization. Wakonda has received several honors over its short history, winning the first ever Golden Horseshoe Business Challenge in upstate NY and being named the National Renewable Energy Laboratory's Entrepreneur of the Year in 2007.
Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.
Cenzic specializes in application security testing for enterprise software, focusing on Software as a Service (SaaS) solutions. The company goes beyond traditional signature-based tools to automatically identify vulnerabilities within applications. Cenzic offers a comprehensive suite of services, including security testing for mobile, web, and cloud applications. In addition to its testing solutions, the company provides security training, penetration testing training, and professional implementation training. Cenzic also offers consulting services, both on-site and remotely, to assist organizations in enhancing their software security practices.
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.
Aperio is the leading provider of digital pathology solutions in hospitals, reference labs, and pharmaceutical and research institutions across the world. Today, our affordable and complete product portfolio improves patient care by enhancing quality assurance, delivering more efficient workflows, facilitating access to new and more targeted therapies, and improving pathologists' skills via lifelong education. Our comprehensive product line features our ScanScope® scanners, Spectrum™ image management (PACS) software, SecondSlide® slide sharing service for pathology, and image analysis tools and services. Aperio's products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications.
Coskata, Inc. is a biology-based renewable energy company, with technology for the production of liquid fuels. Using proprietary microorganisms and transformative bioreactor designs, the company will produce ethanol from a wide variety of input materials to provide economic, environmental, and national security benefits.
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
IMMI, a San Mateo, CA-based mobile-based ad tracking and research firm. The IMMI phone randomly samples 10 seconds of room audio every 30 seconds...these sample are uploaded continuously to the IMMI servers. IMMI also tracks all local TV and radio outlets, and then compares mobile-uploaded signatures with the IMMI-monitored TV and radio broadcasts. The mobile phone also receives a signal from an IMMI "Bluetooth beacon" when the panel member is at home, so the servers can interpret media exposure as "in" or "out-of-home."
Anagran's flow-based traffic management products eliminate the potentially crippling effects of network congestion to enable video, voice, data and wireless traffic to economically scale with flawless quality over converged IP networks. Anagran's products protect all key network traffic by managing end-to-end flows based on their behavior to ensure required quality and performance levels. Its products dynamically manages all network traffic regardless of application, protocol, or format, without using invasive, performance-limiting deep packet inspection(DPI) techniques. Service providers and enterprises can consistently deliver the highest levels of guaranteed performance and quality while significantly reducing capital equipment and recurring network costs. Anagran was founded by Internet pioneer Dr. Larry Roberts, recognized as one of the founding fathers of the Internet.
PowerVision, Inc. is a company that specializes in the development of innovative accommodating intraocular lens technology aimed at restoring vision for individuals affected by presbyopia and cataracts. Based in Belmont, California, PowerVision's flagship product, the FluidVision intraocular lens, utilizes a small amount of fluid within the lens to mimic the natural functioning of a healthy eye, allowing users to dynamically adjust their focus for clear vision at all distances. This technology is designed to address the vision needs of millions, particularly the elderly, who suffer from cataracts and the age-related loss of near vision associated with presbyopia. By offering a solution that potentially eliminates the need for glasses or other forms of vision correction, PowerVision aims to significantly improve the quality of life for those facing these common age-related vision challenges. The company was incorporated in 2002 and was acquired by Alcon Laboratories, Inc. in March 2019.
Zeltiq (pronounced Zel ′teek) Aesthetics, founded in 2005, is a science-based medical device company dedicated to the development of non-invasive procedures for the reduction of unwanted fat tissue. The Zeltiq approach utilizes a patented method called Cryolipolysis™ (the use of precisely controlled cooling to remove fat) that is designed to target only fat cells and not harm the skin or other tissue. The Zeltiq device is cleared by the FDA in the Unites States for various applications related to skin cooling during dermatologic treatments.
Acceleron Pharma Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company is known for luspatercept-aamt, marketed as REBLOZYL, which treats anemia in adult patients with beta-thalassemia. Additionally, it is developing luspatercept-aamt for myelodysplastic syndromes and myelofibrosis, while Sotatercept targets pulmonary arterial hypertension. Acceleron is also advancing ACE-083, a neuromuscular candidate in Phase II trials aimed at Charcot-Marie-Tooth disease. The company's research focuses on biotherapeutics that influence the growth of bone, muscle, fat, and blood vessels to address conditions such as cancer-related bone and muscle loss, as well as various metabolic disorders. Founded in 2003 and based in Cambridge, Massachusetts, Acceleron has established collaborations with Celgene Corporation and Fulcrum Therapeutics to enhance its therapeutic offerings in the pulmonary disease space.